Consultation versus treatment
PUBLISHED SIGNAL
A landing page promises guaranteed approval rather than an assessment.
REVIEW OUTPUT
Capture the exact claim and compare it with the clinical-eligibility wording your team provides.
For partnership, acquisition and clinical-governance teams
A referral should not
promise a prescription.
Check the promises partners make before someone reaches your service. See when a consultation becomes “guaranteed treatment”, eligibility disappears or a campaign lands on the wrong page.
Discuss telehealth & online pharmacy monitoring ↗WHEN THIS BECOMES USEFUL
A change in your programme.
More pages to oversee.
You add affiliates, launch a new service, change clinical eligibility or find that a partner is generating enquiries with the wrong expectations.
CHECKS TO CONFIGURE
What we look for.
What your team gets back.
Medicine versus service promotion
PUBLISHED SIGNAL
A partner’s public medicine promotion may conflict with the configured product, audience and market policy.
REVIEW OUTPUT
Flag the page for the responsible market reviewer. UK and US public-facing promotion need different scopes; a service label alone does not decide whether the promotion is permissible.
Eligibility and exclusions
PUBLISHED SIGNAL
An important age, location or clinical-assessment qualification disappears.
REVIEW OUTPUT
Show the missing qualification against the agreed reference without assessing any patient.
Price and offer mismatch
PUBLISHED SIGNAL
A headline price excludes a required consultation fee or an expired offer remains live.
REVIEW OUTPUT
Identify the URL, observed offer and mismatch with the current terms you supply.
Referral destination
PUBLISHED SIGNAL
An accessible redirect leads to an outdated service page or another brand.
REVIEW OUTPUT
Record the observable route and destination so your partner team can investigate.
Configure these checks around your approved references, supported sources and market rules.
START WITH THE RIGHT REFERENCE
You define the standard.
We check the published content.
Give acquisition teams a specific reason to contact a partner, and help clinical-governance colleagues review the promise without searching through the entire campaign. Use publisher coverage to identify relevant new placements, not patient-level targeting.
Explore Marketing Compliance Explore Marketing IntelligenceWhere the responsibility stays
Treato does not assess patients, approve prescribing, inspect medical records or determine the quality of an individual lead. Referral data is optional and must be authorised and minimised.
See the review handoffWHY THE MARKET MUST BE IN SCOPE
One global rule would be the wrong rule.
UK guidance prohibits advertising prescription-only medicines to the public, while permitting public advertising of non-prescription medicines subject to the applicable requirements. Read the MHRA guidance.
US prescription-drug advertising has a different framework: FDA describes requirements including truthful, non-misleading presentation and fair balance between effectiveness and risk information. Read the FDA’s OPDP FAQs.
For UK public-facing promotion, the ASA also explains why linked destinations and implied prescription-medicine references can matter. Read the ASA guidance.
These examples explain why your qualified reviewers define the policy. Treato does not interpret one universal regulatory rule or provide a compliance certificate.
THE BUYER'S WORKING QUESTION
An offer changes. Which pages need attention?
Start with one campaign and its current eligibility, full price and destination. Verify the specific correction on the partner page rather than treating a partner reply as closure.
CONFIDENCE BEYOND YOUR OWN WEBSITE
Which service, partner claims and referral destinations need the clearest oversight?
Bring a representative partner page and the wording you expect it to use. We will discuss the checks, coverage and outputs your team needs.
Talk to Treato A conversation about your partners, markets and priorities.